Linked Life Data

16950001

Source:http://linkedlifedata.com/resource/pubmed/id/16950001

Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:dateCreated
2006-9-4
pubmed:abstractText
HIV-positive as well as other immunocompromised women and men have increased risk of human papillomavirus (HPV)-associated anogenital and oral cancers. The effectiveness of a HPV vaccine to reduce the incidence of these tumors in immunocompromised individuals may depend on several factors, including the effects of immunocompromise on the response to vaccination, the extent of prior infection with the HPV types included in the vaccine, whether immunocompromised women and men have tumors that contain types of HPV not in the vaccines more often than the general population, and whether or not immunization occurs before immunocompromise is severe. Clinical studies are needed to determine HPV vaccine safety and effectiveness in different populations of immunocompromised women and men.
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:month
Aug
pubmed:issn
0264-410X
pubmed:author
pubmed:issnType
Print
pubmed:day
31
pubmed:volume
24 Suppl 3
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
S3/140-6
pubmed:meshHeading
pubmed:year
2006
pubmed:articleTitle
Chapter 16: HPV vaccines in immunocompromised women and men.
pubmed:affiliation
Department of Medicine, University of California-San Francisco, 505 Parnassus Avenue, San Francisco, CA 94143-0126, USA. joel.palefsky@ucsf.edu
pubmed:publicationType
Journal Article, Review